🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

782 results for “S.A.” Clear

  1. Atumelnant 120 mg tablets, Atumelnant 80 mg tablets, Tablet

    Pharma Mar S.A.

    Classic Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    1 trial
  2. Atumelnant 80 mg tablets, Atumelnant 40 mg tablet, Atumelnant 20 mg tablets, Tablet

    Pharma Mar S.A.

    Classic congenital adrenal hyperplasia

    phase 3 small molecule active

    1 trial
  3. Azacitidin Zentiva 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Azacitidine 25 mg/mL powder for suspension for injection, SY-1425, Placebo for Tamibarotene (SY-1425), AZACITIDINE

    Pharma Mar S.A.

    Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial
  4. BRUKINSA 80 mg hard capsules, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, IMBRUVICA 140 mg hard capsules, Lisaftoclax, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules, Calquence 100 mg hard capsules

    Pharma Mar S.A.

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial
  5. Beltavac Polymerized placebo. It is a saline solution without the allergenic extract, BELTAVAC with polymerized extract From Dermatophagoides

    Pharma Mar S.A.

    Allergic rhinoconjunctivitis due to exposure of house dust mites

    phase 3 small molecule active

    1 trial
  6. Benlysta 200 mg solution for injection in pre-filled pen.

    GlaxoSmithKline Biologicals S.A.

    connective tissue diseases

    phase 3 small molecule active

    1 trial
  7. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes.

    GlaxoSmithKline Biologicals S.A.

    Lung Diseases, Interstitial

    phase 3 small molecule active

    1 trial
  8. Berotralstat, Orladeyo 150 mg hard capsules, Berotralstat, Berotralstat, Berotralstat

    Pharma Mar S.A.

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial
  9. Betahistine dihydrochloride, BETASERC 24 mg, comprimé

    Pharma Mar S.A.

    Menière's disease

    phase 3 small molecule active

    1 trial
  10. Bexicaserin, LP352 (bexicaserin) Placebo Oral Solution

    Pharma Mar S.A.

    Dravet Syndrome

    phase 3 small molecule active

    1 trial
  11. Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed)

    GlaxoSmithKline Biologicals S.A.

    Invasive meningococcal disease (IMD)

    phase 3 small molecule active

    1 trial
  12. Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 320 mg solution for injection in pre-filled pen, Bimzelx 320 mg solution for injection in pre-filled pen, Placebo matching test. 0.9% sodium chloride solution for injection (unauthorized)., Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe

    Pharma Mar S.A.

    Palmoplantar Pustulosis

    phase 3 small molecule active

    1 trial
  13. Biosteron, 10 mg, tabletki, Senaxa PR, 2 mg, tabletki o przedłużonym uwalnianiu

    Pharma Mar S.A.

    Menopause, sleep disorders in the postmenopausal period

    phase 3 small molecule active

    1 trial
  14. Bosulif 500 mg film-coated tablets, Olverembatinib, Bosulif 100 mg film-coated tablets

    Pharma Mar S.A.

    Chronic Phase Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  15. CHLORAMBUCIL, FLUDARABINE PHOSPHATE, Lisaftoclax, ACALABRUTINIB, Lisaftoclax, Lisaftoclax, RITUXIMAB, CYCLOPHOSPHAMIDE MONOHYDRATE, RITUXIMAB

    Pharma Mar S.A.

    Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial
  16. CPT Dermatophagoides pteronyssinus LETI 100 HEP/ml, Formodual 100/6 microgramos/pulsación Solución para inhalación en envase a presión, Montelukast Teva 10 mg comprimidos recubiertos con película EFG, Budesonida Aldo-Unión- 200 microgramos/pulsación suspensión para inhalación en envase a presión., Salbutamol Aldo-Unión 100 microgramos/dosis suspensión para inhalación en envase a presión, AVAMYS 27.5 micrograms/spray, nasal spray suspension, Formodual Nexthaler 200 microgramos/6 microgramos por inhalación po

    Pharma Mar S.A.

    Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinae

    phase 3 small molecule active

    1 trial
  17. CS1003, Placebo, LENVATINIB

    Pharma Mar S.A.

    Unresectable advanced hepatocellular carcinoma

    phase 3 small molecule active

    1 trial
  18. CTX001

    S.A.

    Beta-Thalassemia

    phase 3 mab active

    3 trials
  19. CTX001

    S.A.

    Sickle Cell Disease

    phase 3 mab active

    2 trials
  20. Calquence 100 mg hard capsules

    Pharma Mar S.A.

    Relapsed or Refractory Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial
  21. Calquence 100 mg hard capsules, CYCLOPHOSPHAMIDE, RITUXIMAB, DOXORUBICIN, Placebo, 100mg hard capsules; Identical to IMP apart from the active substance, VINCRISTINE, PREDNISONE

    Pharma Mar S.A.

    Diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial
  22. Carbetocin Nasal Spray

    Pharma Mar S.A.

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial
  23. Carbetocin Nasal Spray, Placebo to match carbetocin 11.4 mg/ml (2ml /vial)

    Pharma Mar S.A.

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial
  24. Casodex 50 mg Film-coated Tablets, Zoladex 10,8 mg implantat

    Pharma Mar S.A.

    Metastatic hormone-sensitive prostate cancer with high tumor load

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources